Based on the liposomal technology platform, InnoMedica has built a diversified pipeline with lead compounds in oncology and neurodegenerative diseases. Clinical trials for the treatment of breast cancer as well as Parkinson's disease are conducted in Swiss hospitals.

Cooperation possibilities

International and national research collaborations have been established and could be further expanded in areas such as cancer, neurodegenerative and auto-inflammatory diseases, paving the way for the development of novel nanocarrier based drugs.

Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2000
  • Number of employees in Switzerland
    20-49

You may also be interested in